Fotagliptin monotherapy with alogliptin as an active comparator in patients with uncontrolled type 2 diabetes mellitus: a randomized, multicenter, double-blind, placebo-controlled, phase 3 trial

作者：Xu, Mingtong; Sun, Kan; Xu, Wenjie; Wang, Chuan; Yan, Dewen; Li, Shu; Cong, Li; Pi, Yinzhen; Song, Weihong; Sun, Qingyuan; Xiao, Rijun; Peng, Weixia; Wang, Jianping; Peng, Hui; Zhang, Yawei; Duan, Peng; Zhang, Meiying; Liu, Jianying; Huang, Qingmei; Li, Xuefeng; Bao, Yan; Zeng, Tianshu; Wang, Kun; Qin, Li; Wu, Chaoming; Deng, Chunying; Huang, Chenghu; Yan, Shuang; Zhang, Wei; Li, Meizi; Sun, Li; Wang, Yanjun; Li, Hongmei; Wang, Guang; Pang, Shuguang; Zheng, Xianling; Wang, Haifang; Wang, Fujun

来源：BMC Medicine, 2023, 21(1): 388.

DOI：10.1186/s12916-023-03089-X

• Dipeptidyl peptidase-4 inhibitors
• Fotagliptin
• Type 2 diabetes mellitus
• HbA1c

Background Dipeptidyl peptidase-4 inhibitors (DPP-4i) have become firmly established in treatment algorithms and national guidelines for improving glycemic control in type 2 diabetes mellitus (T2DM).To report the findings from a multicenter, randomized, double-blind, placebo-controlled phase 3 clinical trial, which was designed to assess the efficacy and safety of a novel DPP-4 inhibitor fotagliptin in treatmentnaive patients with T2DM.Methods Patients with T2DM were randomized to receive fotagliptin (n = 230), alogliptin (n = 113) or placebo (n = 115) at a 2:1:1 ratio for 24 weeks of double-blind treatment period, followed by an open-label treatment period, making up a total of 52 weeks. The primary efficacy endpoint was to determine the superiority of fotagliptin over placebo in the change of HbA1c from baseline to Week 24. All serious or significant adverse events were recorded.Results After 24 weeks, mean decreases in HbA1c from baseline were -0.70% for fotagliptin, -0.72% for alogliptin and -0.26% for placebo. Estimated mean treatment differences in HbA1c were -0.44% (95% confidence interval [CI]: -0.62% to -0.27%) for fotagliptin versus placebo, and -0.46% (95% CI: -0.67% to -0.26%) for alogliptin versus placebo, and 0.02% (95%CI: -0.16% to 0.19%; upper limit of 95%CI < margin of 0.4%) for fotagliptin versus alogliptin. So fotagliptin was non-inferior to alogliptin. Compared with subjects with placebo (15.5%), significantly more patients with fotagliptin (37.0%) and alogliptin (35.5%) achieved HbA1c < 7.0% after 24 weeks of treatment. During the whole 52 weeks of treatment, the overall incidence of hypoglycemia was low for both of the fotagliptin and alogliptin groups (1.0% each). No drug-related serious adverse events were observed in any treatment group.Conclusions In summary, the study demonstrated improvement in glycemic control and a favorable safety profile for fotagliptin in treatment-naive patients with T2DM.Trial registrationClinicalTrail.gov NCT05782192.

• 单位
  安徽医科大学; 内蒙古医学院; 宜春学院; 南昌大学; 武汉大学; 湘潭大学; 5; 1; 上海交通大学; 中山大学; 厦门大学; 吉林大学; 哈尔滨医科大学; 华中科技大学; 深圳市第二人民医院